Policy approach to optimize multiple myeloma treatment sequencing practices
Introduction As a consequence of major therapeutic advances that have transformed multiple myeloma (MM) into a manageable chronic condition, treatment sequencing has become highly complex. According to current practices, novel therapies are predominantly reserved for later disease stages, yet limited evidence suggests that this approach yields optimal long-term outcomes. Understanding the drivers of current practices…












